ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$6.80
-0.49 (-6.72%)
▼
5d:
-16.15%
30d:
+28.3%
90d:
+97.67%
WAIT
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 06, 2026
25d
Smart Money Accumulation
None View Scanner →
Strength: 6.8/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ABCL this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABCL is down 16.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABCL is down 16.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $6.80, which is considered fair relative to its 30-day fair value range of $5.33 to $7.37.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $6.47, while resistance sits at $8.44. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.50 (+54.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $6.47, while resistance sits at $8.44. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.50 (+54.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.33 -
$7.37
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading 54.4% below Wall St target ($10.50)
- WARNING: Recommendation downgraded due to -16.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$5.33 -
$7.37
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.47
Resistance Level
$8.44
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.44
Wall Street Target
$10.50
(+54.4%)
Revenue Growth (YoY)
96.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-181.7%
Share & Embed Analysis
Last updated: July 11, 2026 2:54 AM ET
Data refreshes hourly during market hours. Next update: 3:54 AM
Data refreshes hourly during market hours. Next update: 3:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 58 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
